Inovio Pharmaceuticals, Inc.
NASDAQ:INOBiotechnology
-$0.01 today
- Market cap
- $116.77M
- Beta
- 1.49
- P/E (TTM)
- -8.9
- EPS (TTM)
- -$0.12
Volume 11.56M
Average 2.73M
INO EBITDA
Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.
Inovio Pharmaceuticals, Inc.NASDAQ: INO
EBITDA · Q1 FY2026 · quarter ended Mar 2026
EBITDA remains negative
Q1 FY2026 EBITDA was -$18.94M, compared with -$18.95M a year earlier. Trailing-twelve-month EBITDA was -$81.94M.
Context
- EBITDA amounted to 125425.9% of revenue in FY2025, up 77690.7 pp from a year earlier.
- EBITDA grew in size in 0 of the last 3 fiscal years.
- FY2025 was the smallest annual figure in the 4 fiscal years shown.
What to watch
Whether EBITDA reaches the consensus estimate from 2 analysts of -$37.89M (+53.8%) for the fiscal year ending Dec 2026, a step up from the +21.2% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -$18.94M-519.1% QoQ
- Last fiscal yearDec 2025
- -$81.96M+21.2% YoY
- LTMMar 2026
- -$81.94M+12.2% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +0.1% | +9.5% | +9.5 pp |
| 1 year | +21.2% | +53.8% | +32.6 pp |
| 3-year CAGR | — | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EBITDA history
USD · from the income statement
- Latest · FY2025
- (81.96M) USD
- Year-over-year change
- +21.2%
| Period | Period end | EBITDA | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (81.96M) | +21.2% |
| FY2024 | 2024-12-31 | (103.95M) | +20.3% |
| FY2023 | 2023-12-31 | (130.39M) | +51.9% |
| FY2022 | 2022-12-31 | (270.9M) | +8.7% |
| FY2021 | 2021-12-31 | (296.56M) | — |
EBITDA vs competitors
How INO compares with its peers on the latest reported figures
- INO's LTM Mar 2026 EBITDA of -$81.94M is the 6th highest of the 10 companies compared; the peer median is -$64.35M.
- Its year-over-year change of +12.2% is the 7th highest of 10, against a peer median of +18.9%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $127.04M | +256.7% | — | 102.6% | |
| LTM Mar 2026 | $14.89M | +121.1% | — | 27.2% | |
ACTUActuate Therapeutics Inc | LTM Mar 2026 | -$21.52M | +14.5% | — | — |
| LTM Mar 2026 | -$41.87M | +24.2% | — | 3650.0% | |
| LTM Mar 2026 | -$64.35M | +18.9% | — | 427.9% | |
| LTM Mar 2026 | -$81.94M | +12.2% | — | — | |
IRDOpus Genetics, Inc. | LTM Mar 2026 | -$104.73M | -226.0% | — | 874.0% |
| LTM Mar 2026 | -$108.82M | +2.8% | — | — | |
| LTM Mar 2026 | -$116.42M | -1.3% | — | 632.1% | |
| LTM Mar 2026 | -$117.42M | +23.4% | — | 1859.1% | |
| Peer median (excluding INO) | -$64.35M | +18.9% | — | 632.1% | |
Competitors are the stored peer set for INO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 1.77M | 10.26M | 832.01K | 217.76K | 65.34K |
| Cost of Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | 1.77M | 10.26M | 832.01K | 217.76K | 65.34K |
| Gross Margin | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% |
| Research & Development | 249.24M | 187.65M | 86.68M | 75.62M | 54.21M |
| Selling, General & Admin | 53.75M | 90.19M | 47.58M | 37M | 32.68M |
| Operating Expenses | 302.99M | 277.84M | 144.77M | 112.62M | 86.89M |
| Depreciation & Amortization | 4.73M | 5.5M | 3.5M | 3.13M | 2.99M |
| EBITDA | (296.56M) | (270.9M) | (130.39M) | (103.95M) | (81.96M) |
| EBITDA Margin | -16709.7% | -2639.8% | -15671.8% | -47735.2% | -125425.9% |
| Operating Income | (301.22M) | (267.57M) | (143.94M) | (112.4M) | (86.82M) |
| Operating Margin | -16972.3% | -2607.4% | -17300.3% | -51616.9% | -132871.3% |
| Interest Income | 3.36M | 4.78M | 8.13M | 4.77M | 2.42M |
| Interest Expense | 1.94M | 1.25M | 1.22M | 177.83K | 0 |
| Other Income / Expenses | (2.44M) | (12.24M) | 8.82M | 5.14M | 1.88M |
| Income Before Tax | (303.66M) | (279.82M) | (135.12M) | (107.25M) | (84.95M) |
| Pre-Tax Margin | -17109.9% | -2726.7% | -16239.9% | -49254.3% | -130000.0% |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (303.66M) | (279.82M) | (135.12M) | (107.25M) | (84.95M) |
| Net Margin | -17109.9% | -2726.7% | -16239.9% | -49254.3% | -130000.0% |
| EPS (Basic) | (1.42) | (14.07) | (6.09) | (3.95) | (1.81) |
| EPS (Diluted) | (1.42) | (14.07) | (6.09) | (3.95) | (1.81) |
| Weighted Avg Shares | 214.62M | 19.89M | 22.17M | 27.16M | 468.86M |
| Weighted Avg Shares (Diluted) | 214.62M | 19.89M | 22.17M | 27.16M | 468.86M |
Inovio Pharmaceuticals, Inc.
NASDAQ:INO
Intrinsic Alpha fair value
Locked
Current Price
$1.69
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.